A
19.94
-0.59 (-2.87%)
| Penutupan Terdahulu | 20.53 |
| Buka | 20.53 |
| Jumlah Dagangan | 2,225,003 |
| Purata Dagangan (3B) | 2,807,801 |
| Modal Pasaran | 2,522,912,768 |
| Harga / Pendapatan (P/E TTM) | 55.39 |
| Harga / Pendapatan (P/E Ke hadapan) | 46.30 |
| Harga / Jualan (P/S) | 2.59 |
| Harga / Buku (P/B) | 6.46 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Oct 2025 |
| Margin Keuntungan | -28.83% |
| Margin Operasi (TTM) | -49.96% |
| EPS Cair (TTM) | -1.80 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | -3.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 285.94% |
| Nisbah Semasa (MRQ) | 4.08 |
| Aliran Tunai Operasi (OCF TTM) | -8.29 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 45.63 M |
| Pulangan Atas Aset (ROA TTM) | -14.20% |
| Pulangan Atas Ekuiti (ROE TTM) | -103.82% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Apellis Pharmaceuticals, Inc. | Menurun | Menurun |
AISkor Stockmoo
-1.1
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | -2.5 |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -2.5 |
| Purata | -1.10 |
|
Apellis Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system, which is an integral component of the immune system, at the level of C3, the central protein in the complement cascade. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 13.69% |
| % Dimiliki oleh Institusi | 104.60% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 52.00 (Baird, 160.78%) | Beli |
| Median | 36.00 (80.54%) | |
| Rendah | 19.00 (Mizuho, -4.71%) | Pegang |
| Purata | 37.00 (85.56%) | |
| Jumlah | 10 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 21.39 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| B of A Securities | 21 Jan 2026 | 28.00 (40.42%) | Beli | 20.95 |
| Wells Fargo | 20 Jan 2026 | 26.00 (30.39%) | Beli | 20.47 |
| Cantor Fitzgerald | 13 Jan 2026 | 35.00 (75.53%) | Beli | 21.33 |
| Needham | 13 Jan 2026 | 28.00 (40.42%) | Beli | 21.33 |
| Stifel | 19 Dec 2025 | 48.00 (140.72%) | Beli | 24.65 |
| JP Morgan | 05 Nov 2025 | 36.00 (80.54%) | Beli | 19.95 |
| Mizuho | 03 Nov 2025 | 19.00 (-4.71%) | Pegang | 20.69 |
| Baird | 31 Oct 2025 | 52.00 (160.78%) | Beli | 21.47 |
| Citigroup | 31 Oct 2025 | 45.00 (125.68%) | Beli | 21.47 |
| HC Wainwright & Co. | 31 Oct 2025 | 45.00 (125.68%) | Beli | 21.47 |
| TD Cowen | 31 Oct 2025 | 45.00 (125.68%) | Beli | 21.47 |
| Papar semua | ||||
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BAUMAL CAROLINE | - | 20.47 | -1,882 | -38,525 |
| CHOPAS JAMES GEORGE | - | 20.90 | -1,599 | -33,482 |
| DELONG MARK JEFFREY | - | 20.90 | -3,114 | -65,274 |
| DESCHATELETS PASCAL | - | 20.90 | -3,186 | -67,176 |
| FRANCOIS CEDRIC | - | 20.90 | -18,368 | -384,753 |
| NICHOLSON NUR | - | 20.90 | -4,821 | -100,937 |
| SULLIVAN TIMOTHY EUGENE | - | 20.90 | -6,748 | -141,448 |
| WATSON DAVID O. | - | 20.90 | -8,255 | -173,951 |
| Jumlah Keseluruhan Kuantiti Bersih | -47,973 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,005,546 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 20.87 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| WATSON DAVID O. | Pegawai | 20 Jan 2026 | Jual (-) | 2,475 | 20.47 | 50,663 |
| SULLIVAN TIMOTHY EUGENE | Pegawai | 20 Jan 2026 | Jual (-) | 2,892 | 20.47 | 59,199 |
| NICHOLSON NUR | Pegawai | 20 Jan 2026 | Jual (-) | 2,203 | 20.47 | 45,095 |
| FRANCOIS CEDRIC | Pegawai | 20 Jan 2026 | Jual (-) | 8,182 | 20.47 | 167,486 |
| DESCHATELETS PASCAL | Pegawai | 20 Jan 2026 | Jual (-) | 909 | 20.47 | 18,607 |
| DELONG MARK JEFFREY | Pegawai | 20 Jan 2026 | Jual (-) | 1,334 | 20.47 | 27,307 |
| CHOPAS JAMES GEORGE | Pegawai | 20 Jan 2026 | Jual (-) | 726 | 20.47 | 14,861 |
| BAUMAL CAROLINE | Pegawai | 20 Jan 2026 | Jual (-) | 1,882 | 20.47 | 38,525 |
| WATSON DAVID O. | Pegawai | 13 Jan 2026 | Jual (-) | 5,780 | 21.33 | 123,287 |
| SULLIVAN TIMOTHY EUGENE | Pegawai | 13 Jan 2026 | Jual (-) | 3,856 | 21.33 | 82,248 |
| NICHOLSON NUR | Pegawai | 13 Jan 2026 | Jual (-) | 2,618 | 21.33 | 55,842 |
| FRANCOIS CEDRIC | Pegawai | 13 Jan 2026 | Jual (-) | 10,186 | 21.33 | 217,267 |
| DESCHATELETS PASCAL | Pegawai | 13 Jan 2026 | Jual (-) | 2,277 | 21.33 | 48,568 |
| DELONG MARK JEFFREY | Pegawai | 13 Jan 2026 | Jual (-) | 1,780 | 21.33 | 37,967 |
| CHOPAS JAMES GEORGE | Pegawai | 13 Jan 2026 | Jual (-) | 873 | 21.33 | 18,621 |
| Papar semua | ||||||
| Tarikh | Jenis | Butiran |
|---|---|---|
| 12 Jan 2026 | Pengumuman | Apellis Highlights Commercial Execution and Strategic Priorities at the 44th Annual J.P. Morgan Healthcare Conference |
| 05 Jan 2026 | Pengumuman | Apellis Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference |
| 03 Dec 2025 | Pengumuman | The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN |
| 25 Nov 2025 | Pengumuman | Apellis Pharmaceuticals to Participate in Upcoming Investor Conferences |
| 12 Nov 2025 | Pengumuman | Apellis Announces 5-Year GALE Data Showing SYFOVRE® (pegcetacoplan injection) Delayed Progression of Geographic Atrophy by ~1.5 Years |
| 05 Nov 2025 | Pengumuman | Apellis Pharmaceuticals to Present at the Stifel 2025 Healthcare Conference |
| 30 Oct 2025 | Pengumuman | Apellis Pharmaceuticals Reports Third Quarter 2025 Financial Results |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |